CRSP insider ownership: who sold, why, and what they still hold

What stands out

Routine activity: 57% of sales were under disclosed plans, and no insider sold more than 1% of vested holdings.

A share of stake is shown for 0 of the 5 officers and directors who sold. 14 are left out

Left out: Simeon George, Samarth Kulkarni, James Kasinger, Douglas Treco, Raju Prasad, John Greene, Naimish Patel, Briggs Morrison, Ali Behbahani, Katherine High, Harold Fleming, Maria Fardis, Christian Rommel and Sandesh Mahatme (share of stake is being verified).

Disclosed company stock is not an insider's whole wealth.

Who sold, and how much of their stake

Officers and directors, past 12 months. Their share of stake is being verified and is not shown yet; amounts and trading plans are below.

Samarth Kulkarni

Chief Executive Officer, Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$10.7M48% planned, 52% to cover taxes

Raju Prasad

Chief Financial Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$5.1M87% planned, 13% to cover taxes

James Kasinger

General Counsel and Secretary

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$1.4M54% planned, 46% to cover taxes

Ali Behbahani

Director

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$781KNo plan disclosed

Naimish Patel

Chief Medical Officer

Not confirmed

Share of stake not shown: share of stake is being verified. Why

$363KTo cover taxes

Amounts, filings and trading plans for each seller

Selling by month

Officers and directors, Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.

Disclosed planTo cover taxesNo plan disclosedOne dollar scale for every month; the tallest bar is labeled

Recent activity

Past 30 days, Sep 17, 2026 to Oct 16, 2026

Oct 14, 20262 executives sold 5.1K shares ($253K) to cover taxes on vesting stock.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Samarth Kulkarni Chief Executive Officer, Director	4,098	$49.26	n/a	n/a	Oct 14, 2026	Oct 15, 2026
James Kasinger General Counsel and Secretary	1,040	$49.26	n/a	n/a	Oct 14, 2026	Oct 15, 2026

Oct 6, 2026James Kasinger sold 2K shares ($119K) under a disclosed trading plan. 2K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
James Kasinger General Counsel and Secretary	1,990	$60.04	n/a	n/a	Oct 6, 2026	Oct 8, 2026

Sep 22, 2026James Kasinger sold 10K shares ($626K) under a disclosed trading plan. 10K shares came in from vesting or option exercises the same day, so the holding rose by 0 net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
James Kasinger General Counsel and Secretary	10,400	$60.24	n/a	n/a	Sep 22, 2026	Sep 24, 2026

Sep 17, 2026Ali Behbahani sold 14K shares ($781K) with no plan disclosed. 30K shares came in from vesting or option exercises the same day, so the holding rose by 16K net.

Who	Shares	Price	% of total stake	Total stake after	Trade date	Filed
Ali Behbahani Director	13,679	$57.09	n/a	n/a	Sep 17, 2026	Sep 21, 2026

"% of total stake" is the shares in an event against all the vested shares the person held that day, across every share class and holding entity, after that day's vesting. "n/a" means the person's holdings are not confirmed, or the row is a purchase. "Holdings record incomplete" means more shares were sold than the filings show the person held that day, so a percentage would be wrong.

Common questions

Is the CRISPR Therapeutics AG CEO selling stock?

Yes. Samarth Kulkarni sold 182K shares ($10.7M) in the past 12 months, 48% of it under a trading plan disclosed in the filings.

Why are CRISPR Therapeutics AG insiders selling?

Filings rarely give a reason, and we don't guess at one. What they show is how the sales were made: 57% of sales by value ran under 10b5-1 trading plans disclosed in the filings, 39% were to cover taxes and 4% had no disclosed plan. A trading plan schedules sales in advance.

Are any CRISPR Therapeutics AG insiders buying?

No. Officers and directors reported no purchases in the past 12 months.

The evidence

Who sold5 officers and directors: amount, % of holdings, trading plan

Who sold	Amount	% of holdings	Trading plan
Samarth Kulkarni Chief Executive Officer, Director	$10.7M 182K shares	Not confirmed share of stake is being verified. Why	48% under a disclosed plan, 52% to cover taxes
Raju Prasad Chief Financial Officer	$5.1M 88K shares	Not confirmed share of stake is being verified. Why	87% under a disclosed plan, 13% to cover taxes
James Kasinger General Counsel and Secretary	$1.4M 25K shares	Not confirmed share of stake is being verified. Why	54% under a disclosed plan, 46% to cover taxes
Ali Behbahani Director	$781K 14K shares	Not confirmed share of stake is being verified. Why	No plan disclosed
Naimish Patel Chief Medical Officer	$363K 6.9K shares	Not confirmed share of stake is being verified. Why	To cover taxes

The full ownership picture0 of 14 officers and directors confirmed

Vested shares across all share classes, held directly and through trusts, LLCs and family members, as reported on SEC Forms 3, 4 and 5. Unvested awards and options are never counted as owned shares.

Insider

Held Oct 16, 2025

Sold

Held Oct 16, 2026

Still held

Simeon George

Holdings and share of stake are being verified. Share-of-stake figures and holdings for this company are held back while they are verified. Sales and other transactions for Simeon George are complete.

Director

n/a

Vesting, gifts, unvested awards and holding lines for Simeon George

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Simeon George are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Samarth Kulkarni

Chief Executive Officer, Director

n/a

−182K

n/a

Vesting, gifts, unvested awards and holding lines for Samarth Kulkarni

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Samarth Kulkarni are complete; balances and unit counts will be added when the check is finished.

−30Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
100,000	$19.12	Dec 1, 2027	$3.0M
105,000	$72.94	Mar 20, 2034	$0
55,000	$49.00	Oct 16, 2034	$14K
110,000	$42.12	Mar 14, 2035	$785K
49,500	$67.74	Oct 3, 2035	$0
114,249	$46.24	Mar 20, 2036	$345K

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

James Kasinger

General Counsel and Secretary

n/a

−25K

n/a

Vesting, gifts, unvested awards and holding lines for James Kasinger

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for James Kasinger are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
81,242	$13.62	May 31, 2027	$2.9M
33,333	$72.94	Mar 20, 2034	$0
18,333	$49.00	Oct 16, 2034	$5K
36,666	$42.12	Mar 14, 2035	$262K
16,500	$67.74	Oct 3, 2035	$0
38,499	$46.24	Mar 20, 2036	$116K

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Douglas Treco

Director

n/a

Vesting, gifts, unvested awards and holding lines for Douglas Treco

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Douglas Treco are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Raju Prasad

Chief Financial Officer

n/a

−88K

n/a

Vesting, gifts, unvested awards and holding lines for Raju Prasad

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Raju Prasad are complete; balances and unit counts will be added when the check is finished.

−1.5Kgifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
41,667	$45.15	Mar 14, 2033	$171K
7,493	$44.31	Oct 13, 2033	$37K
36,168	$72.94	Mar 20, 2034	$0
18,333	$49.00	Oct 16, 2034	$5K
36,666	$42.12	Mar 14, 2035	$262K
16,500	$67.74	Oct 3, 2035	$0
38,499	$46.24	Mar 20, 2036	$116K

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

John Greene

Director

n/a

Vesting, gifts, unvested awards and holding lines for John Greene

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for John Greene are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Naimish Patel

Chief Medical Officer

n/a

−6.9K

n/a

Vesting, gifts, unvested awards and holding lines for Naimish Patel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Naimish Patel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
85,000	$54.84	May 28, 2034	$0
18,333	$49.00	Oct 16, 2034	$5K
46,667	$42.12	Mar 14, 2035	$333K
16,500	$67.74	Oct 3, 2035	$0
38,499	$46.24	Mar 20, 2036	$116K

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Briggs Morrison

Director

n/a

Vesting, gifts, unvested awards and holding lines for Briggs Morrison

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Briggs Morrison are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,000	$48.68	Dec 10, 2034	$15K
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Ali Behbahani

Director

n/a

−14K

n/a

Vesting, gifts, unvested awards and holding lines for Ali Behbahani

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Ali Behbahani are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Katherine High

Director

n/a

Vesting, gifts, unvested awards and holding lines for Katherine High

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Katherine High are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Harold Fleming

Director

n/a

Vesting, gifts, unvested awards and holding lines for Harold Fleming

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Harold Fleming are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Maria Fardis

Director

n/a

Vesting, gifts, unvested awards and holding lines for Maria Fardis

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Maria Fardis are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
13,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Christian Rommel

Director

n/a

Vesting, gifts, unvested awards and holding lines for Christian Rommel

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Christian Rommel are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Sandesh Mahatme

Director

n/a

Vesting, gifts, unvested awards and holding lines for Sandesh Mahatme

Holdings and share of stake are being verified. Sales, proceeds, plan and tax status and dates for Sandesh Mahatme are complete; balances and unit counts will be added when the check is finished.

0gifted (net of own trusts)

Stock options (not counted as shares):

Options held	Strike price	Expires	Intrinsic value (estimate)
26,000	$44.81	Oct 16, 2033	$116K
13,000	$54.06	May 30, 2034	$0
13,000	$38.57	Jun 5, 2035	$139K
13,000	$51.84	Jun 5, 2036	$0

Estimate: options held × ($49.26 − strike price), using the most recent insider trade price on Form 4 (Oct 14, 2026), not a market close.

Holdings and share of stake for CRISPR Therapeutics AG are being verified, so no balances, unit counts or percentages are shown. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings.

What explains the selling$18.3M of sales by plan status, purpose, seller and month

Officer and director open-market sales: $18.3M across 315,965 shares. Plan status and stated purpose are separate questions, and a sale can have both.

By plan status

Disclosed plan · $10.4M · 57%

43%

The lighter segment is sales with no plan disclosed in the filing ($7.9M), including tax-related sales outside a plan.

No plan disclosed · $781K

Sales with no 10b5-1 plan and no tax reference in the filing. $781K of it is Ali Behbahani. No plan disclosed is a statement about the filing, not about why the sale happened. Largest such sale: Ali Behbahani, Sep 17, 2026

Taxes

$7.1M of sales (39.1%) cite tax obligations in their footnotes. Example: James Kasinger, Oct 14, 2026

Seller	Shares sold	Proceeds	Under a disclosed plan	Share of total	Sales dates
Samarth Kulkarni Chief Executive Officer, Director	182K	$10.7M	48%	58%	Oct 17, 2025 to Oct 14, 2026
Raju Prasad Chief Financial Officer	88K	$5.1M	87%	28%	Dec 22, 2025 to Mar 23, 2026
James Kasinger General Counsel and Secretary	25K	$1.4M	54%	7%	Feb 19, 2026 to Oct 14, 2026
Ali Behbahani Director	14K	$781K	0%	4%	Sep 17, 2026 to Sep 17, 2026
Naimish Patel Chief Medical Officer	6.9K	$363K	0%	2%	Mar 16, 2026 to May 29, 2026

Sales by month

Month	Sale proceeds	Disclosed plan	To cover taxes	No plan disclosed
Oct 2025	$3.5M	$0	$3.5M	$0
Nov 2025	$0	$0	$0	$0
Dec 2025	$560K	$560K	$0	$0
Jan 2026	$9.1M	$9.1M	$0	$0
Feb 2026	$477K	$0	$477K	$0
Mar 2026	$2.8M	$0	$2.8M	$0
Apr 2026	$0	$0	$0	$0
May 2026	$211K	$0	$211K	$0
Jun 2026	$0	$0	$0	$0
Jul 2026	$0	$0	$0	$0
Aug 2026	$0	$0	$0	$0
Sep 2026	$1.4M	$626K	$0	$781K
Oct 2026	$373K	$119K	$253K	$0

Is this normal? Selling year by year5 earlier years to compare with

In line with the past 5 years. 5 insiders sold; the average is 4 a year.

12 months ending	Shares sold	Insiders who sold	Proceeds
Oct 16, 2026 Latest 12 months	316K	5	$18.3M
Oct 16, 2025 1 year earlier	157K	5	$8.1M
Oct 16, 2024 2 years earlier	168K	4	$11.3M
Oct 17, 2023 3 years earlier	200K	1	$10.2M
Oct 17, 2022 4 years earlier	100K	1	$6.7M
Oct 17, 2021 5 years earlier	994K	7	$147M

Open-market sales (Form 4 code S) by people who were officers or directors, in split-adjusted shares. Earlier years include people who have since left. A sale that an outside holder also reports (a family trust, a fund) is counted with outside holders in every year. Shares, not dollars, are compared, so a change in the stock price doesn't look like a change in selling. Years the filings don't fully cover are shown but left out of the average.

Known gaps and uncertainty14 officers and directors not confirmed

Holdings and share of stake are being verified. Balances, unit counts and every share-of-stake figure for CRISPR Therapeutics AG are held back until that check is finished. Sales, proceeds, plan and tax status, titles and dates come straight from individual filings and are complete.

External context: we only cite outside events when a documented connection exists. None is shown for this period.

Sources and methodology492 filings on record, 40 filed in the 12-month period, and how we read them

All 492 Forms 3, 4 and 5 on record for CRISPR Therapeutics AG (SEC CIK 1674416), filed from Oct 18, 2016 to Oct 15, 2026; 40 of them were filed in the 12 months this page covers, retrieved from SEC EDGAR on Oct 16, 2026. Prices are the ones reported in each filing, often weighted averages.

Holdings. Each holding line (a share class plus an owner, such as a trust or LLC) carries its last reported balance forward. Entities first reported during the period start at zero, so transfers between an insider's own trusts don't count as selling. Lines not reported for three years or more are listed separately and left out of totals.

Sales. A sale counts as under a 10b5-1 plan if its footnote cites one or the filing's Rule 10b5-1 box is checked, and as tax-related if its footnote cites tax obligations or sell-to-cover. Shares withheld by the company for taxes are listed separately. Sales with neither attribute are labeled "no plan disclosed".

Full methodology

Former or inactive filers (24)No filing in 18 months; last reported balances, not in any total

Name	Last filed	Last reported balance
Julianne Bruno	Mar 24, 2025	17,632 shares, last reported balance as of Mar 21, 2025
Phuong Morrow	Oct 17, 2023	4,411 shares, last reported balance as of May 24, 2023
Brendan Smith	Feb 22, 2023	5,072 shares, last reported balance as of Feb 21, 2023
Lawrence Klein	Aug 18, 2022	26,797 shares, last reported balance as of Mar 14, 2022
Bradley Bolzon	Jun 10, 2022	505,099 shares, last reported balance as of Jul 19, 2021
Bradley Bolzon	Jun 10, 2022	1,125,446 shares, last reported balance as of Jul 19, 2021
Tony Ho	Dec 7, 2021	52,364 shares, last reported balance as of Dec 6, 2021
Michael Tomsicek	Aug 10, 2021	1,891 shares, last reported balance as of Aug 6, 2021
Rodger Novak	Jul 1, 2021	573,007 shares, last reported balance as of Jun 30, 2021
Pablo Cagnoni	Nov 21, 2019	No balance on record
Kurt Emster	Jan 18, 2019	108,316 shares, last reported balance as of Jun 5, 2018
Kurt Emster	Jan 18, 2019	1,444,685 shares, last reported balance as of Dec 18, 2018
Vertex Pharmaceuticals (Europe) Ltd	Dec 28, 2018	5,380,940 shares, last reported balance as of Dec 27, 2018
Thomas Woiwode	Jun 15, 2018	736,373 shares, last reported balance as of May 15, 2018
Thomas Woiwode	Jun 15, 2018	3,518,144 shares, last reported balance as of May 7, 2018
Versant Venture Capital IV, L.P.	Apr 26, 2018	3,981,407 shares, last reported balance as of Apr 24, 2018
Bayer Global Investments B.V.	Jan 30, 2018	5,181,275 shares, last reported balance as of Jan 5, 2018
Tyler Dylan-Hyde	Jan 18, 2018	25,204 shares, last reported balance as of Jan 16, 2018
CELGENE CORP /DE/	Dec 7, 2017	3,722,534 shares, last reported balance as of Dec 4, 2017
Kala Subramanian	Jun 19, 2017	No balance on record
Anthony Coles	Jun 2, 2017	140,000 shares, last reported balance as of Oct 24, 2016
Sven Lundberg	Feb 10, 2017	1,010,834 shares, last reported balance as of Oct 24, 2016
GLAXOSMITHKLINE PLC	Oct 26, 2016	3,220,627 shares, last reported balance as of Oct 24, 2016
Hadley Harbor Master Investors (Cayman) L.P.	Oct 24, 2016	744,380 shares, last reported balance as of Oct 24, 2016

Spotted something wrong on this page? Report an error. We check every report against the SEC filing and list what we fix in the corrections log.

CRISPR Therapeutics AG insiders sold $18.3M in the past 12 months. How much of their stake is that?

What stands out

Who sold, and how much of their stake

Selling by month

Recent activity

Common questions

Is the CRISPR Therapeutics AG CEO selling stock?

Why are CRISPR Therapeutics AG insiders selling?

Are any CRISPR Therapeutics AG insiders buying?

The evidence

No plan disclosed · $781K

Taxes

Sales by month